Boston Scientific Corp (BSX)vsInsulet Corporation (PODD)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
PODD
Insulet Corporation
$216.00
-4.21%
HEALTHCARE · Cap: $15.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 641% more annual revenue ($20.07B vs $2.71B). BSX leads profitability with a 14.4% profit margin vs 9.1%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).
BSX
Buy63
out of 100
Grade: C+
PODD
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Margin of Safety
-452.8%
Fair Value
$45.38
Current Price
$216.00
$170.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Revenue surging 31.2% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Trading at 10.0x book value
3.9% earnings growth
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : PODD
The strongest argument for PODD centers on Revenue Growth. Revenue growth of 31.2% demonstrates continued momentum.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : PODD
The primary concerns for PODD are PEG Ratio, Price/Book, EPS Growth. A P/E of 62.1x leaves little room for execution misses.
Key Dynamics to Monitor
BSX profiles as a growth stock while PODD is a hypergrowth play — different risk/reward profiles.
PODD carries more volatility with a beta of 1.44 — expect wider price swings.
PODD is growing revenue faster at 31.2% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (63/100 vs 57/100) and 15.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Insulet Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?